LEXINGTON, Mass.--(BUSINESS WIRE)--NitroMed (NASDAQ: NTMD), said today that the reimbursement and formulary status of BiDil continues to improve. To date, approximately 80% of African Americans who have commercial and Medicare Part D and Medicaid prescription drug insurance coverage in the United States, have affordable access to BiDil. The company defines ‘affordable’ as Tier 2 status, meaning out-of-pocket co-payments for patients are approximately $25. BiDil®, the fixed-dose combination of isosorbide dinitrate (ISDN) and hydralazine hydrochloride (HYD), is approved by the FDA as adjunct therapy in the treatment of heart failure in African Americans to improve survival, reduce hospitalization and improve patient functional status. Heart failure is a life threatening condition that disproportionately burdens African Americans.
